Company · CIK 0001778016 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
NovaBridge Biosciences · NBP
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 SForm 4 → | Sep 21, 4:05 pm EDT | Phillip Andrew DennisChief Medical Officer | 8,209 | $0.71 | $5,828 | 173,427 | −4.52% | |
| Sep 17, 2026 MForm 4 → | Sep 21, 4:05 pm EDT | Phillip Andrew DennisChief Medical Officer | 23,695 | — | — | 181,636 | — | |
| Sep 9, 2026 SForm 4 → | Sep 11, 4:30 pm EDT | Sean Wuxiong CaoChief Bus. Development Officer | 107,978 | $0.74 | $79,904 | 266,467 | −28.8% | |
| Sep 3, 2026 MForm 4 → | Sep 8, 5:51 pm EDT | Sean Wuxiong CaoChief Bus. Development Officer | 339,372 | — | — | 374,445 | — | |
| Aug 31, 2026 SForm 4 → | Sep 1, 6:00 pm EDT | Cong Claire XuEVP, Clinical Development | 3,282 | $0.79 | $2,593 | 304,201 | −1.07% | |
| Aug 30, 2026 MForm 4 → | Sep 1, 6:00 pm EDT | Cong Claire XuEVP, Clinical Development | 9,382 | — | — | 307,483 | — | |
| Aug 22, 2026 MForm 4 → | Aug 25, 4:15 pm EDT | Robert A. LenzDirector | 17,218 | — | — | 17,218 | — | |
| Jul 6, 2026 SForm 4 → | Jul 7, 7:50 pm EDT | Cong Claire XuSVP, Clinical Development | 4,485 | $0.89 | $3,992 | 298,101 | −1.48% | |
| Jul 4, 2026 MForm 4 → | Jul 7, 7:50 pm EDT | Cong Claire XuSVP, Clinical Development | 12,432 | — | — | 302,586 | — | |
| Jun 18, 2026 SForm 4 → | Jun 22, 5:23 pm EDT | Phillip Andrew DennisChief Medical Officer | 8,494 | $0.66 | $5,606 | 157,941 | −5.10% | |
| Jun 17, 2026 MForm 4 → | Jun 22, 5:23 pm EDT | Phillip Andrew DennisChief Medical Officer | 23,695 | — | — | 166,435 | — |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 MForm 4 → | Sep 21, 4:05 pm EDT | Phillip Andrew DennisChief Medical Officer | 10,302 | — | — | 72,120 | — | |
| Sep 3, 2026 MForm 4 → | Sep 8, 5:51 pm EDT | Sean Wuxiong CaoChief Bus. Development Officer | 147,553 | — | — | 135,960 | — | |
| Aug 30, 2026 MForm 4 → | Sep 1, 6:00 pm EDT | Cong Claire XuEVP, Clinical Development | 4,079 | — | — | 28,558 | — | |
| Aug 22, 2026 MForm 4 → | Aug 25, 4:15 pm EDT | Robert A. LenzDirector | 7,486 | — | — | 14,974 | — | |
| Jul 8, 2026 AForm 4 → | Jul 10, 5:00 pm EDT | Mark Arnold HaglerChief Commercial Officer | 949,050 | — | — | 949,050 | — | |
| Jul 8, 2026 AForm 4 → | Jul 10, 5:00 pm EDT | Liwei Lorraine LinGeneral Counsel | 254,780 | — | — | 254,780 | — | |
| Jul 6, 2026 AForm 4 → | Jul 8, 4:26 pm EDT | Srishti GuptaChief Executive Officer, Director | 3,000,000 | — | — | 3,000,000 | — | |
| Jul 4, 2026 MForm 4 → | Jul 7, 7:50 pm EDT | Cong Claire XuSVP, Clinical Development | 5,405 | — | — | 0 | — | |
| Jun 29, 2026 AForm 4 → | Jun 30, 4:15 pm EDT | Wei FuDirector | 3,910,680 | — | — | 1,010,100 | — | |
| Jun 22, 2026 AForm 4 → | Jun 24, 7:22 pm EDT | Sean Wuxiong CaoChief Bus. Development Officer, Director | 362,570 | — | — | 181,290 | — | |
| Jun 17, 2026 MForm 4 → | Jun 22, 5:23 pm EDT | Phillip Andrew DennisChief Medical Officer | 10,302 | — | — | 82,422 | — |